OS Therapies announced that the FDA has granted a Type C Statistical Methods meeting in mid-September 2026 to review 2.5-year overall survival data for its OST-HER2 therapy. This meeting is crucial for determining the appropriate comparator arm, potential RMAT designation, and Rolling Review, which could accelerate regulatory approval for the gene-edited cancer immunotherapy.
OS Therapies (OSTX) announced that the FDA has granted a Type C Statistical Methods meeting for its OST-HER2 therapy, scheduled for mid-September 2026. This meeting is a significant step in the regulatory process, as it will address key statistical methods for interpreting clinical efficacy, potentially leading to RMAT designation and a Rolling Review. The company also expects interim 3-year overall survival data in early September 2026, which, if positive, could further bolster its case. For traders, this news presents a short-term opportunity if the meeting outcomes are favorable, potentially accelerating the drug's path to market. The long-term implication is the potential for a new, approved cancer immunotherapy, but the key risk remains the FDA's ultimate decision and the interpretation of the statistical data.